Laurion Capital Management LP Has $2.11 Million Stock Holdings in Altimmune, Inc. (NASDAQ:ALT)

Laurion Capital Management LP cut its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 56.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 809,685 shares of the company's stock after selling 1,029,919 shares during the period. Laurion Capital Management LP owned approximately 1.51% of Altimmune worth $2,105,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALT. Barclays PLC raised its holdings in shares of Altimmune by 62.0% during the 3rd quarter. Barclays PLC now owns 180,409 shares of the company's stock worth $470,000 after buying an additional 69,014 shares in the last quarter. Dark Forest Capital Management LP raised its holdings in shares of Altimmune by 13.4% during the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company's stock worth $599,000 after buying an additional 27,210 shares in the last quarter. Keudell Morrison Wealth Management acquired a new position in shares of Altimmune during the 3rd quarter worth $36,000. American International Group Inc. acquired a new position in shares of Altimmune during the 2nd quarter worth $84,000. Finally, Quantbot Technologies LP acquired a new position in shares of Altimmune during the 3rd quarter worth $40,000. 66.99% of the stock is owned by institutional investors and hedge funds.

Altimmune Trading Down 0.9 %

Shares of NASDAQ ALT traded down $0.10 during trading on Tuesday, reaching $10.95. The company had a trading volume of 2,778,849 shares, compared to its average volume of 6,529,995. The company's fifty day moving average price is $10.43 and its 200-day moving average price is $5.85. Altimmune, Inc. has a 12 month low of $2.09 and a 12 month high of $14.84.

Analysts Set New Price Targets

ALT has been the subject of a number of recent research reports. B. Riley reaffirmed a "buy" rating and issued a $20.00 target price on shares of Altimmune in a report on Tuesday, February 13th. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Altimmune in a report on Friday, December 1st. Finally, The Goldman Sachs Group began coverage on Altimmune in a report on Wednesday, January 24th. They issued a "neutral" rating and a $13.00 target price for the company.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.

Want to see what other hedge funds are holding ALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altimmune, Inc. (NASDAQ:ALT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.